FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer

Lorenzo Fornaro¹, Caterina Vivaldi^{1

2}, Lorenzo Calvetti³, Alessandro Cappetta³, Alfredo Falcone^{1

4}, Giuseppe Aprile³

Affiliations

¹ Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
² Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
³ Department of Oncology, San Bortolo General Hospital, Vicenza, Italy.
⁴ Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.

Editorial

Lorenzo Fornaro et al. J Thorac Dis. 2019 Dec.

. 2019 Dec;11(12):5694-5700.

doi: 10.21037/jtd.2019.12.103.

Lorenzo Fornaro¹, Caterina Vivaldi^{1

2}, Lorenzo Calvetti³, Alessandro Cappetta³, Alfredo Falcone^{1

4}, Giuseppe Aprile³

¹ Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
² Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
³ Department of Oncology, San Bortolo General Hospital, Vicenza, Italy.
⁴ Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Al-Batran SE, et al. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982686 Clinical Trial.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. 10.3322/caac.21551 - DOI - PubMed
1. Wagner AD, Lordick F, Grabsch HI, et al. Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. Eur J Cancer 2020;124:67-76. 10.1016/j.ejca.2019.09.006 - DOI - PubMed
1. Fornaro L, Vasile E, Aprile G, et al. Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treat Rev 2018;69:90-100. 10.1016/j.ctrv.2018.06.012 - DOI - PubMed
1. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-57. 10.1016/S0140-6736(18)32557-1 - DOI - PubMed
1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. 10.1056/NEJMoa055531 - DOI - PubMed